Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02201849 · ClinicalTrials.gov registry record · Phase 1
A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults
A Phase 1 study of Multiple Sclerosis, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
- 1
- Study location
NCT02201849 is a Phase 1 study of Multiple Sclerosis that has completed, run by Biogen. The registered enrollment target is 104 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02201849, a Phase 1 study of Multiple Sclerosis, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the safety, tolerability, and pharmacokinetics of ALKS 8700, a monomethyl fumerate (MMF) molecule.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Study Drug
- DRUG Active Control
Study Locations (1)
Texas
- Alkermes Investigational Site - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2014-07 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02201849
The ClinicalTrials.gov registry entry for NCT02201849 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (82% lower). The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02201849 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02201849 about?
NCT02201849 is a clinical study titled "A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults". This study will evaluate the safety, tolerability, and pharmacokinetics of ALKS 8700, a monomethyl fumerate (MMF) molecule.
What is the current status of trial NCT02201849?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2014-07. Estimated completion is 2014-12.
What conditions does trial NCT02201849 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT02201849?
The interventions under investigation include: Placebo (DRUG), Study Drug (DRUG), Active Control (DRUG).
Who is sponsoring clinical trial NCT02201849?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02201849 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
RECRUITING · Phase 1
-
Molecular Imaging of NET Using [C-11]MRB-PET in MS
RECRUITING · Phase 1
-
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.